Dec 26 (Reuters) - Eurand NV:
* FDA issues complete response letter to GlaxoSmithkline for Eurand's EUR-1048
* Says FDA also has advised GSK that review of another collaborative product,
EUR-1000, has been extended into 2009
* Says GSK informed it submitted its response; anticipates FDA will take up to
60 days to review response and take action on NDA
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2008. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* FDA issues complete response letter to GlaxoSmithkline for Eurand's EUR-1048
* Says FDA also has advised GSK that review of another collaborative product,
EUR-1000, has been extended into 2009
* Says GSK informed it submitted its response; anticipates FDA will take up to
60 days to review response and take action on NDA
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2008. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.